TheiaLife Sciences
Clinical-stage ophthalmology company developing novel therapeutics and biomaterials to address unmet needs in eye diseases. Active programs include an oral small-molecule therapy for pediatric myopia with completed Phase 2 and planned Phase 3 activity, ophthalmic topical formulations, and recombinant-collagen corneal implants. The company pursues preclinical and clinical development, named-patient/early access programs, and strategic partnering for global development and commercialization.
Industries
N/A
Nr. of Employees
small (1-50)
TheiaLife Sciences
8 The Green STE 14267, Dover, Delaware 19901, USA
Products
Oral small-molecule therapy for pediatric myopia (7-methylxanthine / ND10)
Oral tablet formulation developed to increase scleral biomechanical strength and slow axial elongation in children; completed Phase 2 and extensive real-world use with planned global Phase 3.
Topical formulation for dry eye disease (ND101 eye drops)
Ophthalmic topical formulation intended to increase tear production, stabilize tear film, reduce hyperosmolarity and provide anti-inflammatory effects based on preclinical studies.
Topical posterior-segment candidate for neovascular AMD and pterygium (XP37 eye drops)
Topical ophthalmic candidate designed to reach posterior segment and anterior-segment targets to reduce VEGF expression and angiogenesis as a non-invasive alternative to intravitreal injections or surgery.
Recombinant-collagen corneal implant / film (rHCT3 series)
Bioengineered recombinant-collagen implant designed to mimic corneal stroma, reduce rejection risk, and provide an on-demand alternative to donor corneas for corneal repair and blindness indications.
Topical keratoconus candidate (rHCT3-2 eye drops)
Topical agent intended to promote collagen crosslinking and inhibit metalloproteinases to strengthen and stabilize the cornea in keratoconus.
Oral small-molecule therapy for pediatric myopia (7-methylxanthine / ND10)
Oral tablet formulation developed to increase scleral biomechanical strength and slow axial elongation in children; completed Phase 2 and extensive real-world use with planned global Phase 3.
Topical formulation for dry eye disease (ND101 eye drops)
Ophthalmic topical formulation intended to increase tear production, stabilize tear film, reduce hyperosmolarity and provide anti-inflammatory effects based on preclinical studies.
Topical posterior-segment candidate for neovascular AMD and pterygium (XP37 eye drops)
Topical ophthalmic candidate designed to reach posterior segment and anterior-segment targets to reduce VEGF expression and angiogenesis as a non-invasive alternative to intravitreal injections or surgery.
Recombinant-collagen corneal implant / film (rHCT3 series)
Bioengineered recombinant-collagen implant designed to mimic corneal stroma, reduce rejection risk, and provide an on-demand alternative to donor corneas for corneal repair and blindness indications.
Topical keratoconus candidate (rHCT3-2 eye drops)
Topical agent intended to promote collagen crosslinking and inhibit metalloproteinases to strengthen and stabilize the cornea in keratoconus.
Services
Partner identification, licensing, co-development and regional commercialization collaborations to advance ophthalmology assets.
Conduct and support of clinical studies for ophthalmic indications, including global Phase 3 planning and patient enrollment support.
Administration of physician-requested access to investigational medicines where permitted by local regulations, including assessment and supervised supply.
Analytical method development and parallel synthesis/screening of candidate molecules to accelerate lead selection.
Partner identification, licensing, co-development and regional commercialization collaborations to advance ophthalmology assets.
Conduct and support of clinical studies for ophthalmic indications, including global Phase 3 planning and patient enrollment support.
Administration of physician-requested access to investigational medicines where permitted by local regulations, including assessment and supervised supply.
Analytical method development and parallel synthesis/screening of candidate molecules to accelerate lead selection.
Expertise Areas
- Ophthalmology drug discovery
- Pediatric myopia therapeutics
- Corneal tissue engineering and biomaterials
- Formulation development for oral and topical ophthalmic products
Key Technologies
- Oral small-molecule therapeutics
- Topical ophthalmic formulations (eye drops)
- Recombinant collagen biomaterials and implants
- Metabolic and genetic engineering
News & Updates
Press release describing engagement with a transaction advisory firm to support strategic partnering for the company's myopia asset after interest following publication of real-world data.
Conference presentation describing analysis of clinical data suggesting efficacy of 7-MX in a subgroup of children with reduced myopia progression and less eye elongation.
Real-world/clinical data on oral 7-methylxanthine associated with slowed myopia progression in Danish children published in a peer-reviewed ophthalmology journal.
Mini-review on role of 7-methylxanthine in myopia prevention and control.
Press release describing engagement with a transaction advisory firm to support strategic partnering for the company's myopia asset after interest following publication of real-world data.
Conference presentation describing analysis of clinical data suggesting efficacy of 7-MX in a subgroup of children with reduced myopia progression and less eye elongation.
Real-world/clinical data on oral 7-methylxanthine associated with slowed myopia progression in Danish children published in a peer-reviewed ophthalmology journal.
Mini-review on role of 7-methylxanthine in myopia prevention and control.